Show simple item record

dc.contributor.authorDenkert, C
dc.contributor.authorLiedtke, C
dc.contributor.authorTutt, A
dc.contributor.authorvon Minckwitz, G
dc.date.accessioned2017-10-02T14:50:03Z
dc.date.issued2017-06-17
dc.identifier.citationLancet (London, England), 2017, 389 (10087), pp. 2430 - 2442
dc.identifier.issn0140-6736
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/845
dc.identifier.eissn1474-547X
dc.identifier.doi10.1016/s0140-6736(16)32454-0
dc.description.abstractTriple-negative breast cancer is a heterogeneous disease and specific therapies have not been available for a long time. Therefore, conventional chemotherapy is still considered the clinical state of the art. Different subgroups of triple-negative breast cancer have been identified on the basis of protein expression, mRNA signatures, and genomic alterations. Important elements of triple-negative breast cancer biology include high proliferative activity, an increased immunological infiltrate, a basal-like and a mesenchymal phenotype, and deficiency in homologous recombination, which is in part associated with loss of BRCA1 or BRCA2 function. A minority of triple-negative tumours express luminal markers, such as androgen receptors, and have a lower proliferative activity. These biological subgroups are overlapping and currently cannot be combined into a unified model of triple-negative breast cancer biology. Nevertheless, the molecular analysis of this disease has identified potential options for targeted therapeutic intervention. This has led to promising clinical strategies, including modified chemotherapy approaches targeting the DNA damage response, angiogenesis inhibitors, immune checkpoint inhibitors, or even anti-androgens, all of which are being evaluated in phase 1-3 clinical studies. This Series paper focuses on the most relevant clinical questions, summarises the results of recent clinical trials, and gives an overview of ongoing studies and trial concepts that will lead to a more refined therapy for this tumour type.
dc.formatPrint-Electronic
dc.format.extent2430 - 2442
dc.languageeng
dc.language.isoeng
dc.publisherELSEVIER SCIENCE INC
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectLymphocytes, Tumor-Infiltrating
dc.subjectHumans
dc.subjectUbiquitin-Protein Ligases
dc.subjectBRCA2 Protein
dc.subjectAntineoplastic Agents
dc.subjectNeoadjuvant Therapy
dc.subjectGene Expression Profiling
dc.subjectGenomics
dc.subjectMutation
dc.subjectFemale
dc.subjectMolecular Targeted Therapy
dc.subjectTriple Negative Breast Neoplasms
dc.subjectBiomarkers, Tumor
dc.titleMolecular alterations in triple-negative breast cancer-the road to new treatment strategies.
dc.typeJournal Article
dcterms.dateAccepted2016-11-09
rioxxterms.funderThe Institute of Cancer Research
rioxxterms.identifier.projectUnspecified
rioxxterms.versionofrecord10.1016/s0140-6736(16)32454-0
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2017-06
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfLancet (London, England)
pubs.issue10087
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR
pubs.publication-statusPublished
pubs.volume389
pubs.embargo.termsNot known
dc.contributor.icrauthorTutt, Andrew


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record